Mupirocin-mediated downregulation of claudin-14 enhances chemosensitivity in human colorectal cancer cells.
Mizukami Yuko, Ando Tomoka, Tosaki Shiemi, Ishikawa Yoshinobu, Shinoda Takehiro, Shirouzu Mikako, Yoshino Yuta, Morimoto Kazushi, Endo Satoshi, Matsunaga Toshiyuki, Matsuhashi Nobuhisa, Ikari Akira
Abstract
Claudin-14 (CLDN14), a tight junction protein, contributes to cell proliferation and chemoresistance in human colorectal cancer (CRC)-derived DLD-1 cells. However, small molecules targeting CLDN14 remain unexplored. Here, we identified mupirocin (MUP), a clinically approved topical antibiotic, as a modulator of CLDN14 protein expression. Quartz crystal microbalance analysis revealed interaction between MUP and recombinant CLDN14 protein with a dissociation constant (Kd) of 2.59 ± 0.54 μM. MUP did not alter CLDN14 mRNA levels but reduced CLDN14 protein stability. Pharmacological inhibition of clathrin-mediated endocytosis and lysosomal degradation significantly reversed the MUP-induced reduction of CLDN14 protein. These results suggest MUP accelerates endocytosis-lysosomal degradation of CLDN14 protein. Other antibiotics failed to decrease CLDN14 expression. Functionally, MUP increased paracellular permeability to mineral ions and enhanced the transepithelial flux of doxorubicin (DXR), an anthracycline anticancer drug, and lucifer yellow, an aqueous small compound. In DLD-1 spheroids, MUP reduced intracellular oxidative stress and nuclear factor erythroid 2-related factor 2 (Nrf2) expression. Consequently, MUP promoted intracellular accumulation of DXR and significantly potentiated its cytotoxic effects in spheroids. Moreover, MUP enhanced the antitumor efficacy of other chemotherapeutic agent oxaliplatin. Sulforaphane, an Nrf2 activator, attenuated the MUP-induced enhancement of anticancer efficacy. These findings suggest that MUP enhances anticancer drug sensitivity in CRC through lysosome-dependent downregulation of CLDN14 protein and suppression of oxidative stress signaling.
Key Findings
- Mupirocin (MUP) interacts with claudin-14 (CLDN14) protein and reduces its stability via lysosome-dependent degradation.
- MUP enhances paracellular permeability and increases intracellular accumulation and cytotoxicity of chemotherapeutic drugs like doxorubicin and oxaliplatin in colorectal cancer cells.
- MUP reduces oxidative stress and Nrf2 expression, and Nrf2 activation attenuates MUP's enhancement of anticancer drug efficacy.
Clinical Significance
Mupirocin may serve as a novel adjuvant to improve chemosensitivity in colorectal cancer by targeting CLDN14 and modulating oxidative stress pathways, potentially enhancing the effectiveness of existing chemotherapy agents.
Citation
Mizukami Yuko, Ando Tomoka, Tosaki Shiemiet al.. Mupirocin-mediated downregulation of claudin-14 enhances chemosensitivity in human colorectal cancer cells. Biochimica et biophysica acta. Molecular cell research. 2026-Aug.